About: Recomendaciones para reumatólogos sobre el manejo farmacológico durante la emergencia sanitaria COVID-19: opinión grupo de expertos

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recomendaciones para reumatólogos sobre el manejo farmacológico durante la emergencia sanitaria COVID-19: opinión grupo de expertos Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Recomendaciones para reumatólogos sobre el manejo farmacológico durante la emergencia sanitaria COVID-19: opinión grupo de expertos
Creator	Haga, S Yamamoto, N Nakai-Murakami, C Osawa, Y Sata, T Tokunaga, K
Source	Elsevier; PMC
abstract	Resumen La infección por Coronavirus 2019 (COVID-19) es una pandemia inesperada que ha provocado un estado de emergencia y generado cambios drásticos en los protocolos de atención clínica. Para su tratamiento se ha descrito el papel de algunos medicamentos usados habitualmente en artritis reumatoide, lupus eritematoso sistémico y otras enfermedades autoinmunes sistémicas. Debido a ello, existe un inminente riesgo de desabastecimiento, por lo cual el objetivo de esta revisión narrativa y opinión de expertos es formular recomendaciones generales clínicas y administrativas sobre el manejo de pacientes ambulatorios con enfermedad autoinmune o inflamatoria sistémica en el contexto de la pandemia por COVID-19. Abstract Coronavirus 2019 (COVID-19) is an unexpected pandemic that has caused a state of emergency, as well as generating drastic changes in clinical care protocols. Some drugs commonly used in rheumatoid arthritis, systemic lupus erythematosus, and other systemic autoimmune diseases have been described for its treatment. Therefore, there is an imminent risk of shortages. The aim of this narrative review and expert opinion is to present general recommendations on the clinical and administrative management of outpatients with autoimmune or systemic inflammatory disease, in the context of the COVID-19 pandemic.
has issue date	2020-06-26(xsd:dateTime)
bibo:doi	10.1016/j.rcreu.2020.05.021
has license	els-covid
sha1sum (hex)	0ec75e3fe15f28099577831c58aac1369018f686
schema:url	https://doi.org/10.1016/j.rcreu.2020.05.021
resource representing a document's title	Recomendaciones para reumatólogos sobre el manejo farmacológico durante la emergencia sanitaria COVID-19: opinión grupo de expertos
has PubMed Central identifier	PMC7318971
resource representing a document's body	covid:0ec75e3fe15f28099577831c58aac1369018f686#body_text
is schema:about of	named entity 'Correo' named entity 'Expert' named entity 'Massachusetts' named entity 'LOS' named entity 'NARRATIVE REVIEW' named entity 'DRUGS' named entity 'HEALTH' named entity 'lupus' named entity 'EMERGENCY' named entity 'PHARMACOLOGICAL' named entity 'COVID-19' named entity 'Coronavirus 2019' named entity 'RHEUMATOLOGISTS' named entity 'infección' named entity 'COVID-19' named entity 'Massachusetts General Hospital' named entity 'igual' named entity 'COVID-19' named entity 'COVID-19' named entity 'AAK1' named entity 'infección' named entity 'COVID-19' named entity 'COVID-19' named entity 'hacer' named entity 'COVID-19' named entity 'COVID-19' named entity 'belimumab' named entity 'tocilizumab' named entity 'COVID-19' named entity 'emite' named entity 'las guías' named entity 'COVID-19' named entity 'SARS' named entity 'esta' named entity 'el tiempo' named entity 'COVID-19' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'COVID-19' named entity 'celecoxib' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'anakinra' named entity 'SARS-CoV' named entity 'infección' named entity 'abatacept' named entity 'COVID-19' named entity 'igual' named entity 'COVID-19' named entity 'COX2' named entity 'COVID-19' named entity 'esta' named entity 'adalimumab' named entity 'adalimumab' named entity 'infección' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'infección' named entity 'Estados Unidos' named entity 'infliximab' named entity 'COVID-19' named entity 'Colombia' named entity 'COVID-19' named entity 'Colombia' named entity 'kinasa' named entity 'COVID-19' named entity 'primera línea' named entity 'inflammatory disease' named entity 'COVID-19' named entity 'imminent risk' named entity 'systemic lupus erythematosus' named entity 'Coronavirus 2019' named entity 'Some' named entity 'caused' named entity 'The' named entity 'rheumatoid arthritis' named entity 'COVID-19' named entity 'esta'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software